This Neulasta market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the increasing prevalence of chemotherapy-induced neutropenia, a higher global incidence of cancer, growing awareness of the risks of neutropenia during cancer treatment, the availability of supportive government funding for biologics, and the early adoption of biologics in developed regions.
The projected growth during the forecast period can be attributed to the expansion of biosimilars in emerging markets, increasing demand for cost-effective cancer supportive care, rising global healthcare expenditure, more regulatory approvals for biosimilars, and growing patient awareness of biosimilar alternatives. Key trends expected during this period include the development of prefilled syringes for easier administration, advances in drug delivery systems such as on-body injectors, the adoption of digital platforms for patient education, the use of AI in biologics research and development as well as supply chain optimization, and strategic partnerships between biologic and biosimilar companies.
The increasing prevalence of cancer is expected to drive the growth of the Neulasta market in the future. Cancer, a group of diseases marked by abnormal cell growth, often spreads to other parts of the body. Factors such as aging populations, unhealthy lifestyles, and environmental influences are contributing to the rise in cancer cases. Pegfilgrastim biosimilars such as Neulasta are vital for cancer patients undergoing chemotherapy, as they help prevent chemotherapy-induced neutropenia by stimulating the production of white blood cells and reducing the risk of infections. For example, the Australian Institute of Health and Welfare projected that by 2034, Australia would have around 209,000 new cancer diagnoses, a significant increase from the estimated 169,000 cases expected in 2024. Cancer is also expected to account for about 30% of all deaths in the country by 2024. As a result, the rising incidence of cancer will contribute to the growth of the Neulasta market.
The growing use of personalized medicine is another factor expected to drive the growth of the Neulasta market. Personalized medicine involves customizing treatments based on individual patient characteristics, improving efficacy while reducing side effects. Advances in genomics and biotechnology are enabling more precise treatments for complex diseases, including cancer and rare genetic disorders. Neulasta (pegfilgrastim) supports personalized medicine by effectively preventing chemotherapy-induced neutropenia with tailored dosing and advanced delivery systems such as autoinjectors, which align treatment with each patient's specific chemotherapy regimen. For instance, the Personalized Medicine Coalition reported that in 2023, the U.S. FDA approved 16 new personalized treatments for rare diseases, up from 6 in 2022. Seven of these new treatments were cancer drugs. This trend toward personalized medicine is expected to drive the Neulasta market.
An important trend in the Neulasta market is the development of innovative drug delivery technologies, such as prefilled autoinjectors, which are helping companies gain a competitive edge. Prefilled autoinjectors are self-injection devices that come preloaded with medication, designed to make it easier for patients to administer the treatment themselves. For example, Coherus Biosciences announced in March 2023 that the FDA had approved a single-dose, prefilled autoinjector version of its pegfilgrastim biosimilar, Udenyca, for the treatment and prevention of febrile neutropenia, a common complication of chemotherapy. This device allows patients to administer pegfilgrastim the day after chemotherapy, reducing the risk of febrile neutropenia, and features push-on-skin activation for reliable and immediate delivery of the full dose.
The key player in the neulasta market is Amgen Inc.
North America was the largest region in the neulasta market in 2024. The regions covered in neulasta report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neulasta market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Neulasta is a prescription medication used to reduce the risk of infection in chemotherapy patients by stimulating the production of white blood cells. It is typically administered through an injection, often with an on-body injector or prefilled syringe, and is known for its effectiveness and convenience in managing neutropenia.
The primary indications for Neulasta include chemotherapy-induced neutropenia, bone marrow transplantation, and other related conditions. Chemotherapy-induced neutropenia occurs when chemotherapy lowers neutrophil levels, a type of white blood cell essential for fighting infections, which increases the risk of severe infections and complications during cancer treatment. Neulasta is available as an injectable solution in pre-filled syringes or pens, and it is distributed through hospitals, oncology clinics, specialty pharmacies, and home healthcare services. It is used by various patient groups, including both adult and pediatric patients.
The neulasta market research report is one of a series of new reports that provides neulasta market statistics, including neulasta industry global market size, regional shares, competitors with a neulasta market share, detailed neulasta market segments, market trends and opportunities, and any further data you may need to thrive in the neulasta industry. This neulasta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The neulasta market consists of sales of prefilled syringes, injection devices, and biosimilar products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the increasing prevalence of chemotherapy-induced neutropenia, a higher global incidence of cancer, growing awareness of the risks of neutropenia during cancer treatment, the availability of supportive government funding for biologics, and the early adoption of biologics in developed regions.
The projected growth during the forecast period can be attributed to the expansion of biosimilars in emerging markets, increasing demand for cost-effective cancer supportive care, rising global healthcare expenditure, more regulatory approvals for biosimilars, and growing patient awareness of biosimilar alternatives. Key trends expected during this period include the development of prefilled syringes for easier administration, advances in drug delivery systems such as on-body injectors, the adoption of digital platforms for patient education, the use of AI in biologics research and development as well as supply chain optimization, and strategic partnerships between biologic and biosimilar companies.
The increasing prevalence of cancer is expected to drive the growth of the Neulasta market in the future. Cancer, a group of diseases marked by abnormal cell growth, often spreads to other parts of the body. Factors such as aging populations, unhealthy lifestyles, and environmental influences are contributing to the rise in cancer cases. Pegfilgrastim biosimilars such as Neulasta are vital for cancer patients undergoing chemotherapy, as they help prevent chemotherapy-induced neutropenia by stimulating the production of white blood cells and reducing the risk of infections. For example, the Australian Institute of Health and Welfare projected that by 2034, Australia would have around 209,000 new cancer diagnoses, a significant increase from the estimated 169,000 cases expected in 2024. Cancer is also expected to account for about 30% of all deaths in the country by 2024. As a result, the rising incidence of cancer will contribute to the growth of the Neulasta market.
The growing use of personalized medicine is another factor expected to drive the growth of the Neulasta market. Personalized medicine involves customizing treatments based on individual patient characteristics, improving efficacy while reducing side effects. Advances in genomics and biotechnology are enabling more precise treatments for complex diseases, including cancer and rare genetic disorders. Neulasta (pegfilgrastim) supports personalized medicine by effectively preventing chemotherapy-induced neutropenia with tailored dosing and advanced delivery systems such as autoinjectors, which align treatment with each patient's specific chemotherapy regimen. For instance, the Personalized Medicine Coalition reported that in 2023, the U.S. FDA approved 16 new personalized treatments for rare diseases, up from 6 in 2022. Seven of these new treatments were cancer drugs. This trend toward personalized medicine is expected to drive the Neulasta market.
An important trend in the Neulasta market is the development of innovative drug delivery technologies, such as prefilled autoinjectors, which are helping companies gain a competitive edge. Prefilled autoinjectors are self-injection devices that come preloaded with medication, designed to make it easier for patients to administer the treatment themselves. For example, Coherus Biosciences announced in March 2023 that the FDA had approved a single-dose, prefilled autoinjector version of its pegfilgrastim biosimilar, Udenyca, for the treatment and prevention of febrile neutropenia, a common complication of chemotherapy. This device allows patients to administer pegfilgrastim the day after chemotherapy, reducing the risk of febrile neutropenia, and features push-on-skin activation for reliable and immediate delivery of the full dose.
The key player in the neulasta market is Amgen Inc.
North America was the largest region in the neulasta market in 2024. The regions covered in neulasta report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neulasta market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Neulasta is a prescription medication used to reduce the risk of infection in chemotherapy patients by stimulating the production of white blood cells. It is typically administered through an injection, often with an on-body injector or prefilled syringe, and is known for its effectiveness and convenience in managing neutropenia.
The primary indications for Neulasta include chemotherapy-induced neutropenia, bone marrow transplantation, and other related conditions. Chemotherapy-induced neutropenia occurs when chemotherapy lowers neutrophil levels, a type of white blood cell essential for fighting infections, which increases the risk of severe infections and complications during cancer treatment. Neulasta is available as an injectable solution in pre-filled syringes or pens, and it is distributed through hospitals, oncology clinics, specialty pharmacies, and home healthcare services. It is used by various patient groups, including both adult and pediatric patients.
The neulasta market research report is one of a series of new reports that provides neulasta market statistics, including neulasta industry global market size, regional shares, competitors with a neulasta market share, detailed neulasta market segments, market trends and opportunities, and any further data you may need to thrive in the neulasta industry. This neulasta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The neulasta market consists of sales of prefilled syringes, injection devices, and biosimilar products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Neulasta Market Characteristics4. Neulasta Market Trends and Strategies5. Neulasta Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Neulasta Pricing Analysis & Forecasts30. Global Neulasta Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Neulasta Market32. Recent Developments in the Neulasta Market
3. Neulasta Market Biologic Drug Characteristics
6. Global Neulasta Growth Analysis and Strategic Analysis Framework
8. Neulasta Market Segmentation
9. Global Neulasta Epidemiology of Clinical Indications
10. Neulasta Market Regional and Country Analysis
11. Asia-Pacific Neulasta Market
12. China Neulasta Market
13. India Neulasta Market
14. Japan Neulasta Market
15. Australia Neulasta Market
16. South Korea Neulasta Market
17. Western Europe Neulasta Market
18. UK Neulasta Market
19. Germany Neulasta Market
20. France Neulasta Market
21. Eastern Europe Neulasta Market
22. North America Neulasta Market
23. USA Neulasta Market
24. Canada Neulasta Market
25. South America Neulasta Market
26. Middle East Neulasta Market
27. Africa Neulasta Market
28. Neulasta Market Competitive Landscape and Company Profiles
29. Global Neulasta Market Pipeline Analysis
33. Neulasta Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Neulasta Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on neulasta market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for neulasta? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neulasta market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Chemotherapy-Induced Neutropenia; Bone Marrow Transplantation; Other Indications2) by Formulation: Injectable Solution; Pre-Filled Syringes or Pens
3) by Distribution Channel: Hospitals; Oncology Clinics; Specialty Pharmacies; Home Healthcare Services
4) by End User Patients: Adult Patients; Pediatric Patients
Key Companies Mentioned: Amgen Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
